Fitzroy

Researchers are evaluating the effects of oral neflamapimod, a specific inhibitor of the enzyme p38 alpha kinase, on recovery after moderate to severe acute ischemic stroke. The study aims to determine whether neflamapimod can improve residual physical disability and cognitive dysfunction following such strokes. This is a Phase 2, double-blind, placebo-controlled clinical trial targeting adults who have recently experienced an ischemic stroke in the brain's anterior circulation. Participants will receive either neflamapimod capsules containing 40 mg of the active drug or placebo capsules that look identical but contain no active ingredients. The treatment will be administered over a 12-week period. The study compares motor recovery and other functional outcomes between the neflamapimod and placebo groups to assess the investigational drug's impact. During the study, participants will undergo various assessments including the Fugl-Meyer Assessment of Motor Recovery, the Timed Up and Go Test, and the National Institutes of Health Stroke Scale motor score. These evaluations will measure changes from baseline to Week 12 to track motor and cognitive recovery. Safety monitoring and adherence will be conducted through regular evaluations. The total participation period covers enrollment through the end of treatment at 12 weeks.

Researchers are evaluating the safety, tolerability, and therapeutic effects of a combination treatment using BNT113 and pembrolizumab compared to pembrolizumab alone for patients with unresectable recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that is positive for human papillomavirus 16 (HPV16+) and expresses the PD-L1 protein with a combined positive score of 1 or higher. This Phase II/III trial includes patients whose cancer cannot be treated with local therapies and who have not received prior systemic anticancer therapy for their current disease condition. The trial consists of two parts. Part A is a non-randomized Safety Run-In Phase to confirm the safety and tolerability of BNT113 combined with pembrolizumab at the selected dose. Part B is a randomized phase that compares BNT113 plus pembrolizumab against pembrolizumab alone as first-line treatment. Patients in Part A continue their treatment without randomization. Treatments are given by intravenous injection or infusion, and patients may receive either combination therapy or monotherapy for up to 24 months. There is also an optional pre-screening phase to test tumor samples for HPV16 DNA and PD-L1 expression before entering the main trial. Participants undergo regular assessments including tumor measurements based on RECIST 1.1 criteria confirmed by independent review. Researchers monitor treatment-emergent adverse events for up to 27 months in Part A and evaluate overall survival and progression-free survival for up to 48 months in Part B. Tumor tissue samples are collected before treatment to confirm eligibility. The study involves ongoing safety monitoring and efficacy evaluations throughout the treatment and follow-up periods.

Researchers are investigating BGB-16673, a targeted protein degrader aimed at treating various B-cell cancers including marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström macroglobulinemia, and diffuse large B-cell lymphoma. The study includes both Phase 1 and Phase 2 parts to determine safe and effective dosing and to evaluate the drug's response in patients. The trial is conducted under the new company name BeOne Medicines, previously known as BeiGene. The treatment involves oral administration of BGB-16673. Phase 1 focuses on dose escalation and safety expansion to identify the maximum tolerated dose and recommended dose for expansion over approximately 28 days to 3 years. Phase 2 includes expansion cohorts to assess overall response rates over about 3 years. Participants may have prior treatments including Bruton tyrosine kinase inhibitors and other anticancer therapies depending on their cancer type and study phase. Participants will be monitored closely with assessments of adverse events from the first dose until 30 days after the last dose or before starting new therapy, whichever comes first, for up to 47 weeks. The study measures tolerability, dosing recommendations, and treatment response. Eligibility assessments include performance status and measurable disease, with safety and response evaluations continuing through both phases for up to three years.

Researchers are conducting a Phase 1 study to evaluate the safety and antitumor activity of UB-VV111, a gene therapy that creates CD19 CAR T cells inside the body. The study focuses on patients with relapsed or refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL). The trial also investigates the combination of UB-VV111 with rapamycin, an FDA-approved drug, in these CD19-positive B-cell malignancies. Participants will receive UB-VV111 gene therapy alone or combined with rapamycin. This dose-escalation and dose-confirmation study aims to find the appropriate dosing and assess the treatment effects. The trial is open-label and conducted at multiple centers, focusing on relapsed or refractory disease states in LBCL and CLL patients. During the study, researchers will monitor participants for common adverse events for up to two years after UB-VV111 administration. Patients will undergo evaluations including disease measurement using established criteria, organ function tests, and performance status assessments. Safety and treatment responses will be closely tracked throughout the trial period to understand the therapy's impact and tolerability.

Researchers are evaluating the safety, tolerability, and effectiveness of sonrotoclax alone and combined with other drugs in patients with relapsed or refractory multiple myeloma with a specific chromosomal translocation called t(11;14). This Phase 1b/2 study focuses on patients whose disease has returned or not responded to previous treatments, aiming to understand how well sonrotoclax works in these settings. The study assesses sonrotoclax given by mouth daily, either alone or combined with dexamethasone (given once weekly by mouth or intravenously), carfilzomib (weekly intravenous), daratumumab (weekly under the skin), or pomalidomide (daily by mouth). Different combinations are tested to find safe and effective dosing. The study includes dose-escalation and cohort-expansion phases to explore various treatment regimens. Participants will be closely monitored for side effects and treatment responses over time. Researchers will track dose-limiting toxicities during the first 28 days, adverse events up to 30 days after the last dose, and long-term responses over approximately 4 years. Assessments include measuring disease markers and overall response rates. Safety and efficacy data will guide future treatments for this patient population.

Researchers are evaluating the pharmacokinetics and safety of a subcutaneous injection of durvalumab combined with recombinant human hyaluronidase (rHu) in adults with different types of solid tumors. This Phase I multicenter study aims to find a subcutaneous durvalumab dose that provides drug levels similar to intravenous durvalumab. The study includes participants with non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and limited-stage small cell lung cancer (LS-SCLC). The study is divided into two parts: Part 1 involves dose escalation with two planned dose levels of subcutaneous durvalumab in participants with NSCLC, HCC, or LS-SCLC. Part 2 focuses on dose expansion in participants with unresectable HCC, starting once the appropriate dose is identified. Durvalumab plus rHu is given under the skin, while intravenous durvalumab and tremelimumab are administered by infusion for some participants. Participants will be monitored from the first dose through approximately 17 months of durvalumab administration. Researchers will measure drug concentrations over time and the lowest concentration before the next dose. Participants will undergo assessments including safety evaluations, organ function tests, and disease measurements. The study also tracks side effects and overall drug exposure to evaluate safety and pharmacokinetics during treatment.

Researchers are evaluating the safety and effectiveness of HLX22 combined with trastuzumab and chemotherapy as the first treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 2, double-blind, randomized, and multiregional study compares this combination against trastuzumab and chemotherapy with or without pembrolizumab. The study aims to measure how well the treatments work in controlling the disease and improving survival for up to five years. Participants will be randomly assigned to one of two groups. One group receives HLX22 at 15 mg/kg every three weeks along with trastuzumab, chemotherapy (XELOX regimen), and possibly a placebo for pembrolizumab. The other group receives a placebo for HLX22 plus trastuzumab, chemotherapy (XELOX), and possibly pembrolizumab every three weeks. Treatment continues until the disease worsens, unacceptable side effects occur, withdrawal of consent, or other protocol-specified reasons. Throughout the study, participants will undergo regular assessments including tumor scans reviewed by an independent committee to evaluate progression-free survival and overall survival over up to five years. Other evaluations include safety monitoring and organ function tests. The study tracks how long patients live without disease progression and overall survival, aiming to better understand the benefits and risks of HLX22 combined with current standard treatments.

Researchers are evaluating how well oral icotrokinra works, its safety, and how well patients tolerate it in adults and adolescents with moderately to severely active ulcerative colitis, a chronic condition where the colon lining becomes inflamed and develops ulcers. This is a Phase 3 study aimed at finding effective treatments for this condition using a rigorous comparison. Participants will receive either icotrokinra tablets or placebo tablets taken by mouth. The study includes an induction phase and a maintenance phase, with adults participating in a randomized, double-blind, placebo-controlled design, while adolescents join an open-label maintenance study. Throughout the study, researchers will monitor clinical remission rates at 12 weeks during induction and at 40 weeks during maintenance. Participants will undergo assessments including endoscopic evaluations and pregnancy tests for females of childbearing potential. Safety and tolerability will be closely observed, with the total study duration covering both induction and maintenance periods.

Researchers are evaluating insulin icodec, a once-weekly insulin injection, compared to insulin glargine, a once-daily injection, in adults with type 1 diabetes. The study aims to see how well weekly insulin icodec controls blood sugar levels compared to daily insulin glargine when both are combined with insulin aspart. This phase 3 study will last about 26 weeks, or roughly 8.5 months. Participants will receive either insulin icodec or insulin glargine, both given as subcutaneous injections. All participants will also use insulin aspart as a subcutaneous injection. The study compares these two insulin regimens to assess their effects on blood sugar control over the 26-week period. During the study, researchers will monitor changes in glycosylated hemoglobin (HbA1c) from the start of the study to week 26. Participants will follow the study protocol including self-measured plasma glucose profiles. Safety and efficacy will be evaluated throughout the treatment period to understand the impact of the insulin regimens on blood sugar control and participant health.

Researchers are evaluating AZD0120, a dual-targeted CAR-T therapy against BCMA and CD19, compared to standard treatments for participants with relapsed refractory multiple myeloma (RRMM). This Phase III, randomized, open-label global study compares AZD0120 with established regimens including DKd (daratumumab, carfilzomib, dexamethasone), DPd (daratumumab, pomalidomide, dexamethasone), PVd (pomalidomide, bortezomib, dexamethasone), and Kd (carfilzomib and dexamethasone). The study aims to assess the safety and effectiveness of AZD0120 in this patient population. Participants will receive either AZD0120 CAR-T cell therapy or one of the standard drug regimens. The treatments involve combinations of biologic and drug therapies targeting multiple myeloma. The study is designed to evaluate outcomes such as progression-free survival and minimal residual disease negativity rate over periods of up to three years. During the study, participants will be closely monitored with regular assessments to evaluate disease progression and treatment response. Researchers will track progression-free survival over three years and measure minimal residual disease negativity rates at nine months, among other safety and efficacy evaluations. Participants will have laboratory tests and clinical evaluations to ensure safety and to measure treatment effects throughout the study duration.